EDNRB and pulmonary arterial hypertension: Herein, we used bosentan as the endothelin antagonist, which targets two endothelin receptors, EdnrA and EdnrB, with a similar binding affinity (35–38) and is clinically used to treat pulmonary arterial hypertension [39].